GTBP — GT Biopharma, Inc.
Is GTBP overbought or oversold? Here is the current MarketMoodz read.
GT Biopharma, Inc. (GTBP) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.54. The rating moved from Oversold to Strong Oversold on November 17, 2026.
- Public ratingStrong Oversold (as of November 17, 2026)
- Last close$3.54
- Last changeMoved from Oversold to Strong Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
GT Biopharma, Inc. (GTBP) is a small-cap clinical-stage biotech whose equity value is highly dependent on discrete clinical and regulatory milestones and on financing outcomes. With no specific company filings or material updates provided, the assessment leans on sector conditions: risk-on intraday flows may provide short-term support, but broader investor preference is favoring large-cap pharma and defensive healthcare names. Convertible-debt and dilution pressure noted across mid/small-cap biotech raises financing risk; limited liquidity and typical microcap volatility increase downside sensitivity. Potential upside would come from positive clinical readouts, partnership/M&A interest, or clear non-dilutive financing, while downside would result from adverse trial news, cash-runway-driven dilution, or continued sector rotation away from small biotechs.
Key factors
- Small-cap clinical-stage biotech profile with outcome-driven valuation (clinical/regulatory readouts are primary value drivers)
- No company-specific filings or recent material disclosures available in the provided data, increasing reliance on sector trends and general biopharma dynamics
- Market environment showing risk-on sentiment but sector flows favor large-cap pharma and defensive names, reducing breadth support for microcaps
- Sector theme noting convertible-debt and dilution pressure across diagnostics/biotech which could affect financing options and share dilution risk
- Retail interest and earnings-driven day-to-day momentum can provide short-term support and liquidity spikes for the equity
- Limited visible commercial revenue stream or durable competitive moat based on provided information — value contingent on clinical progress or partnerships
Risks
- Clinical trial failure or negative regulatory outcome that would materially reduce valuation
- Cash runway constraints leading to dilutive financing (convertible or equity) that depresses share value
- Low liquidity and high volatility typical of microcap biotechs, amplifying downside on negative news
- Sector rotation into large-cap pharma and defensive ETFs reducing investor appetite for small biotechs
- Increased convertible-debt activity in the sector that could translate to adverse financing terms or hedging-related selling pressure
- Competitive advances by larger pharma/biotech that reduce addressable market or make partnerships less likely
- Lack of publicly available, recent financial disclosures (per provided data) increases uncertainty about balance sheet and burn rate
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for GTBP — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.